Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Kymera Therapeutics' Q2 2025 earnings call highlights clinical progress, Gilead and Sanofi partnerships, and financial strength, setting a strong stage ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Shares in Gilead Sciences were a massive 9% higher in Friday’s early trading after the US biotech major lifted its full-year financial guidance.

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.